TRAE | Patients Treated With Lenvatinib 24 mg Once Daily (N = 26) | |
---|---|---|
Patients with any-grade TRAE, n (%) | 26 (100) | |
Patients with any TRAE ≥ grade 3, n (%) | 16 (61.5) | |
Preferred term, n (%) | Any grade | Grade 3 or 4 |
Hypertension | 22 (84.6) | 10 (38.5) |
Dysphonia | 16 (61.5) | 0 |
Palmar-plantar erythrodysesthesia syndrome | 15 (57.7) | 3 (11.5) |
Proteinuria | 15 (57.7) | 3 (11.5) |
Thrombocytopenia | 13 (50.0) | 1 (3.8) |
Decreased appetite | 12 (46.2) | 0 |
Fatigue | 12 (46.2) | 0 |
Hypothyroidism | 12 (46.2) | 0 |
Decreased weight | 6 (23.1) | 0 |
Diarrhea | 6 (23.1) | 0 |
Anemia | 5 (19.2) | 1 (3.8) |
Malaise | 5 (19.2) | 0 |
Nausea | 5 (19.2) | 0 |
Peripheral edema | 5 (19.2) | 0 |
Myalgia | 4 (15.4) | 0 |
Stomatitis | 4 (15.4) | 0 |
Alopecia | 3 (11.5) | 0 |
Constipation | 3 (11.5) | 0 |
Epistaxis | 3 (11.5) | 0 |
Headache | 3 (11.5) | 0 |
Rash | 3 (11.5) | 1 (3.8) |
Upper abdominal pain | 3 (11.5) | 0 |